Location History:
- Ann Arbor, MI (US) (2017 - 2022)
- Wallingford, PA (US) (2017 - 2022)
Company Filing History:
6 out of 15,475 
5 out of 528 
4 out of 3,381 
Years Active: 2017-2025
Title: Unveiling the Innovations of Inventor Michael Holinstat
Introduction:
Meet Michael Holinstat, a prolific inventor based in Wallingford, PA, USA, with a remarkable track record of 8 patents under his belt. His groundbreaking work in the field of platelet function inhibitors has garnered attention for its potential in treating various diseases like platelet hemostasis and thrombosis.
Latest Patents:
1. Inhibitors of Platelet Function: Michael's latest patents introduce small molecule inhibitors of platelet function, paving the way for innovative methods to combat diseases related to platelet aggregation. These compounds, such as those of Formula (I), show promise in treating conditions like thrombosis.
2. 4-((2-Hydroxy-3-Methoxybenzyl)amino)benzenesulfonamide Derivatives: Another patent by Michael focuses on potent and selective inhibitors of 12-lipoxygenase, an enzyme involved in various physiological responses. These compounds exhibit high potency against 12-LOX and offer potential therapeutic benefits for diseases like skin diseases, diabetes, and cancer.
Career Highlights:
Michael Holinstat has made significant contributions to the field of biochemistry and pharmaceuticals through his work at renowned institutions like Thomas Jefferson University and Eastern Virginia Medical School. His expertise in developing novel inhibitors and pharmaceutical compounds has positioned him as a leading figure in the industry.
Collaborations:
Throughout his career, Michael has collaborated with esteemed professionals like Theodore Holman and David Joseph Maloney. Together, they have synergized their expertise to drive innovation and advance the field of platelet function inhibitors.
Conclusion:
Inventor Michael Holinstat's dedication to pioneering advancements in platelet function inhibitors underscores his commitment to improving healthcare outcomes. His patented inventions represent a significant step forward in the treatment of diseases associated with platelet aggregation, offering hope for more effective therapeutic interventions in the future.